TCTMD

EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism

BOTHELL, Wash.-- EKOS Corporation announced today the EKOS EkoSonic® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The EkoSonic® System, ...
Nasdaq

REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices Each year, approximately 350,000 patients in the United ...
Nasdaq

HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs.
BioWorld

Real-world study: Less bleeding with Ekos than Flowtriever in PE

An analysis of real-world data pulled from Truveta’s electronic health records of 30 U.S. health care systems found that patients treated for pulmonary embolism (PE) using Boston Scientific Corp.’s ...
ksn.com

REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...